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Abstract
Exposure to nicotine during smoking causes a multitude of metabolic changes that are poorly understood. We quantified
and analyzed 198 metabolites in 283 serum samples from the human cohort KORA (Cooperative Health Research in the
Region of Augsburg). Multivariate analysis of metabolic profiles revealed that the group of smokers could be clearly
differentiated from the groups of former smokers and non-smokers. Moreover, 23 lipid metabolites were identified as
nicotine-dependent biomarkers. The levels of these biomarkers are all up-regulated in smokers compared to those in former
and non-smokers, except for three acyl-alkyl-phosphatidylcholines (e.g. plasmalogens). Consistently significant results were
further found for the ratios of plasmalogens to diacyl-phosphatidylcolines, which are reduced in smokers and regulated by
the enzyme alkylglycerone phosphate synthase (alkyl-DHAP) in both ether lipid and glycerophospholipid pathways.
Notably, our metabolite profiles are consistent with the strong down-regulation of the gene for alkyl-DHAP (AGPS)i n
smokers that has been found in a study analyzing gene expression in human lung tissues. Our data suggest that smoking is
associated with plasmalogen-deficiency disorders, caused by reduced or lack of activity of the peroxisomal enzyme alkyl-
DHAP. Our findings provide new insight into the pathophysiology of smoking addiction. Activation of the enzyme alkyl-
DHAP by small molecules may provide novel routes for therapy.
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Introduction
An estimated one billion men and 250 million women
worldwide are daily tobacco smokers, primarily through cigarettes
[1]. Cigarette smoking is the cause of about 90 percent of the
world’s lung cancer cases, and accounts for one in four cancer
deaths worldwide [2,3,4]. Smoking decreases high density
lipoprotein (HDL) carrying cholesterol, thus increasing the risk
for many cardiovascular diseases. The incidence of acute
myocardial infarction is about 2.5 times higher in smokers than
in non-smokers, according to a study grounded on the population-
based research platform KORA (Cooperative Health Research in
the Region of Augsburg) [5,6,7].
Metabolites are the intermediate or end points of metabolism,
and biomarkers refer to indicators of a particular disease state or a
particular physiological state of an organism. In cigarette smoke,
there are more than 5,000 chemicals, including about 70 cancer-
causing agents (carcinogens), among which nicotine and its major
metabolite cotinine and carbon monoxide are found to be
biomarkers of cardiovascular damage [8,9]. After cigarette smoke
is inhaled, nicotine is carried deep into the lungs, where it is
absorbed into the bloodstream and carried to almost every part of
the body. Nicotine reaches the brain within 10 seconds, and has
been found in breast milk as well as in the umbilical blood of
newborn babies.
There have been a few studies addressing metabolite changes in
smokers. Several metabolites, including carbon monoxide, metab-
olites of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone (NNK), and total cotinine (cotinine plus
cotinine-N-glucuronide), were investigated in urine samples of a
study in which the number of cigarettes consumed was reduced
daily. No significant differences were observed, presumably due to
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e3863a potential compensation mechanism [10,11]. It was suggested
that people who are trying to cut back by consuming fewer
cigarettes per day change their behavior by inhaling longer and
deeper, which is known to alter a smoker’s exposure to
carcinogens.
Due to a lack of powerful tools for analyses, large-scale
metabolic screens of smoking phenotype in blood plasma or
serum have not been reported to date. In recent years, technology
improvements have greatly advanced the field of metabolomics,
which involves rapid, high-throughput characterization of the
small molecular metabolites identified in an organism [12,13,14].
Metabolite profiles are very much dependent on the genetic
background and the physiological status of the organism. They are
also dependent on environmental factors and are regarded as the
ultimate result of cellular regulation, resulting in the observed
phenotypes [15,16,17,18]. However, the classes and numbers of
detected metabolites are still limited to date.
In the current study, we investigated concentrations of 198
metabolites in 283 KORA samples by targeted metabolomics, in
order to study the influence of cigarette smoking on blood serum
profiles. We systematically analyzed the metabolic profiles
employing several statistical methods, such as simple calculation
of the correlations of metabolites and the ratios of metabolite
concentration, metabolites clustering, multivariate statistics (Partial
Least Squares Discriminant Analysis, PLS-DA, Principal Compo-
nent Analysis, PCA and Correspondence Analysis, CA)
[14,19,20,21,22], as well as ANOVA [23] and Wilcoxon tests
[24,25]. We investigated the populations at individual and group
levels and observed significant changes of two types of metabolites,
which are intermediates or end products of glycerophospholipid-
and ether lipid-metabolism, in smokers compared to former and
non-smokers. Based on our own data and as well on another gene
expression study, we propose a molecular mechanism explaining
the altered lipid balance in smokers.
Results
Clustering of human metabolites in the KORA population
In total, 283 human blood sera were analyzed and 198
metabolites were obtained for each individual (see Materials and
Methods). An correlation matrix of all metabolite concentrations
was calculated based on the 283 individuals and hierarchical
clusteringresulted intwomain clusters, A and B (Figures1A,S1and
S2). Cluster A consists of lipids and has two sub clusters:
glycerophospholipids (cluster A1) and sphingolipids (cluster A2),
except for 14 acyl-alkyl- (ae) phosphatidylcholines. For classes and
biochemical names of the metabolites see Table S1. In general,
metabolites with similar polarhead groups and thesametypeofside
chains were found to be closely clustered. For example, sub cluster
A11 consists of the samehead group phosphatidylcholines (PC), and
is differentiated by those with diacyl- (aa) vs. ae-phosphatidylcholines
(Figure 1A); three sub clusters were obtained in A12, phosphatidyl-
ethanolamines (PE) and phosphatidylinositols (PI) withaabonds, the
third sub cluster comprises lipidswithone side chain, butthree head
groups (PC, PE and PA for phosphatidic acids). Cluster B also
consists of two sub clusters–acylcarnitines together with amino acids
(cluster B1) and biogenic amines (cluster B1 and B2), and
prostaglandins with sugars (cluster B2), except for nine glyceropho-
spholipids. Related classes of metabolites are generally clustered
together based on the population-based KORA samples.
When the influence of smoking on the human metabolome was
investigated, 28 current cigarette smokers were removed from the
Figure 1. Comparison of clustering results. (A) Classification of the 198 metabolites based on population-based KORA samples (n=283). Similar
classes of metabolites are shown with the same color. The numbers in brackets next to the metabolite name indicate how many metabolites are
included. In some clusters, one other class of metabolite was clustered together, did not indicated here. (B) Classification of the 198 metabolites by
removing the 28 current smokers from the date set (n=255). Similar clusters in plots A and B are shown with gray shadows. For more details, see
Figures S1 to S4.
doi:10.1371/journal.pone.0003863.g001
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clustering of metabolites was consequently observed (Figure 1B
and Figures S3, S4). Overall, cluster B did not change, except that
six sphingomyelins and two glycerophospholipids moved from
cluster A to B2. A decreased level of correlation of the
glycerophospholipids was seen in cluster A (Figures S1, S2, S3
and S4). Furthermore, some glycerophospholipids were found to
be closely related with sphingolipids in clusters A21. This
suggested that some lipids were affected because of the removal
from the dataset of the data for the 28 smokers.
To investigate the significance of observed differences between
the full dataset and that with the removal of the 28 current
smokers, 200 permutations were conducted by randomly sampling
255 individuals (i.e. removing 28 samples without replacement)
from the ‘‘283 dataset’’, and a correlation matrix of all metabolites
was calculated. The resulting 1986198 matrix was correlated with
the one obtained using the original ‘‘283 dataset’’. Each of the two
matrices was first converted into a vector. The Pearson’s
correlation coefficient of these vectors was then calculated. The
normal distribution of these 200 coefficients has been used in a t-
test as a null hypothesis. It is significantly different from the one in
which the 28 smokers were removed (p-value of t-test was 2.28E-4)
and correlated with the pair-wise matrices of the original 283
dataset, suggesting that the observed differences after the removal
of the 28 smokers are not a random effect.
Metabolic profiles differentiate current smokers from
former and non-smokers
When Partial Least Squares Discriminant Analysis (PLS-DA),
Principal Component Analysis, (PCA) and Correspondence
Analysis (CA) were applied for the 283 individuals with 198
metabolites, current, former and non-smokers could be separated
to a certain extent (Figure 2A, PCA and CA results are shown in
Figure S5). When the three groups based on the mean value of the
metabolites were characterized, CA results showed that smokers
separated clearly from former and non-smokers by the first CA
component, which accounted for 89 percent of the total variance
(Figure 2B).
The first component is dominated by a set of metabolites
(Table 1), indicating that these metabolites are primarily
responsible for separating smokers from former and non-smokers.
The higher the CA score, the more it contributes to the separation.
Figure 2. Multivariate analysis results. (A) Two dimensional PLS-DA results of 283 individuals. The 28 current smokers are displayed in red, while
154 former smokers and 101 non-smokers are indicated in blue and green, respectively. Three dimensional PLS-DA results are shown in Figure S5A.
(B) CA results of the current, former and non-smoker groups.
doi:10.1371/journal.pone.0003863.g002
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the total variance of CA that distinguishes non-smokers from
former smokers in the dataset. The second component is
dominated by two sphingolipids with high CA2 scores (Table 1),
suggesting these two metabolites are sensitive for distinguishing
former smokers from non-smokers.
Novel nicotine-dependent biomarkers
Potential nicotine-dependent (ND) biomarkers were identified
using various statistical methods (Table 1). For example, for
metabolite PC aa C32:1, the mean values of the current smoker
(S), former smoker (fS) and non-smoker (nS) were 71.09, 52.77 and
45.52 mM, respectively; ANOVA tests of these mean values and
the results showed that these differences are highly significant (p-
value 6.9E-07). Wilcoxon tests of the differences between 28 S and
101 nS also indicated high significance with (p-value 1.5E-06);
Wilcoxon tests for the differences between 154 fS and 101 nS are
also significant at the 5% level. In addition to PC aa C32:1, seven
metabolites differing between fS and nS were found to be
significant at 5% level based on the Wilcoxon test (Table 1).
Especially two sphingomyelins, SM (OH, COOH) C16:1 and SM
OH C2:3, and one PC ae C38:2 had the most significant p-values
in the Wilcoxon test comparing former smokers and non-smokers.
These two sphingomyelins were also identified by CA method (i.e.
have high CA2 scores, see above).
For the 23 potential ND biomarkers, the mean values of
current, former and non-smoker groups are clearly distinct
(Table 1). Differences were observed based on the median value
of the three groups, with a few outliers for each metabolite (see box
plots in Figure 3). The biomarker levels in current smokers are
almost all up regulated compared to those in former and non-
smokers, with three acyl-alkyl-phosphatidylcholines (PC ae C40:6,
PC ae C36:2 and PC ae C38:2) down regulated.
Ratios of acyl-alkyl- to diacyl-phosphatidylcholines are
reduced in smokers compared to non-smokers
To further investigate the observed three plasmalogens
deficiency, we calculated ratios of all pair metabolite concentra-
tions and correlated them with nicotine consumption (see
Materials and Methods). The most significantly correlated pairs
of metabolites are listed in Table 2 and are illustrated in Figure 4.
For example, with the smoker phenotype, ratio PC ae C40:6/PC
aa C32:1 is positively significantly correlated (r is 0.333, and p-
value of t-test is 9.5E-09), while ratio PC aa C32:1/PC ae C40:6 is
negatively significantly correlated (r is 20.378 with p-value 5.0E-
11). These data indicate that in smokers, the relative concentration
of PC ae C40:6 was significantly lower than PC aa C32:1, which is
inconsistent with the observation in single metabolite analysis
(Table 1). Moreover, the ratios of metabolite PC ae C40:6 with
other 13 metabolites were all significant, suggesting that
Table 1. Identified nicotine-dependent potential biomarkers
Metabolite Mean6Standard Error (mM) CA scores ANOVA Wilcoxon (p-value)
Smoker Former smoker Non-smoker CA1 CA2 p-value S-nS fS-nS
PC aa C32:1 71.0966.01 52.7761.90 45.5261.55 1.13 0.17 6.9E-07 1.5E-06 0.039
PC aa (OH, COOH) C30:3 241.3617.7 192.164.53 174.464.07 1.41 0.17 4.1E-07 4.4E-05 0.024
PC aa C34:1 530.4638.8 417.5610.2 389.369.26 2.06 0.04 2.0E-06 3.6E-05 0.22
PC aa C34:0 72.3764.37 57.5761.61 52.261.43 0.78 0.10 3.6E-06 7.2E-06 0.079
PC aa C36:1 172.6611.7 139.463.34 133.663.07 0.93 20.07 4.9E-05 1.9E-04 0.34
PC aa C36:2 490.3633.2 402.668.56 406.869.12 1.08 20.48 5.4E-04 2.3E-02 0.49
PC aa C36:3 299.8624.5 245.764.95 244.1766.38 0.94 20.28 7.7E-04 5.7E-03 0.72
PC aa C38:2 70.1063.54 58.2161.16 58.7361.34 0.37 20.17 3.6E-04 2.7E-03 0.69
PC aa C38:3 152.669.80 121.863.04 116.663.42 0.94 20.07 6.8E-05 1.4E-04 0.26
PC aa C40:4 12.5960.85 9.5760.45 8.6360.29 0.40 0.03 5.4E-04 4.3E-06 0.21
PC aa C40:5 35.4062.42 27.5861.02 25.2660.70 0.58 0.04 1.2E-04 7.6E-05 0.34
PC aa C32:0 33.0461.99 28.5960.71 26.5360.66 0.28 0.06 1.2E-03 1.8E-03 0.21
PE aa C34:2 3.2460.44 2.2060.10 1.9860.12 0.29 0.01 1.7E-04 2.8E-03 0.083
PE aa C36:2 6.5560.95 4.4060.21 3.8860.22 0.43 0.02 6.9E-05 7.0E-04 0.14
PE aa C36:4 3.8060.41 2.7360.12 2.4460.16 0.27 0.02 4.3E-04 8.0E-05 0.015
PE aa C38:4 7.4760.82 5.3860.27 4.7560.27 0.38 0.03 5.9E-04 4.1E-04 0.056
PI aa C36:4 3.8460.35 2.9360.12 2.6460.13 0.22 0.02 1.0E-03 2.0E-03 0.18
PI aa C38:4 33.3962.58 26.9260.93 25.4660.85 0.43 0.01 3.0E-03 1.4E-03 0.37
PC ae C40:6 7.9060.69 8.7860.21 8.7860.21 20.33 0.10 1.4E-02 5.3E-04 0.024
PC ae C36:2 25.0361.73 24.6260.53 26.57 60.60 20.28 0.19 7.3E-02 0.037 0.011
PC ae C38:2 12.6160.78 12.4260.24 13.6960.33 20.22 0.16 8.2E-03 0.059 4.5E-03
SM (OH, COOH) C16:1 33.8962.41 28.3860.77 23.6460.91 0.53 0.24 1.1E-06 3.4E-05 1.6E-05
SM OH C20:3 195.969.81 179.164.48 157.164.74 0.54 0.47 2.9E-04 2.3E-04 1.2E-03
Metabolite names are listed in the first column (for classes and biochemical names, see Table S1). Mean values with standard error of metabolite concentrations in mM
for each group, current smoker (S), former smoker (fS) and non-smoker (nS), are shown in columns 2 to 4, respectively. The first and second component score of the CA
are given in columns 5 and 6. In the last three columns, p-values of ANOVA and Wilcoxon tests are indicated.
doi:10.1371/journal.pone.0003863.t001
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PLoS ONE | www.plosone.org 4 December 2008 | Volume 3 | Issue 12 | e3863Figure 3. Box plots of the 23 identified nicotine-dependent potential biomarkers. For each metabolite, box plot of current (S), former (fS)
and non-smoker (nS) groups is illustrated. For each group, the five parameters are the smallest concentration of the metabolite, lower quartile,
median, upper quartile, and largest observation. The points outside the quartiles are outliers.
doi:10.1371/journal.pone.0003863.g003
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compared to other 11 diacylated phosphatidylcholines and two
sphingomyelines. For the other two acyl-alkylated phosphatidyl-
cholines, PC ae C38:2 and PC ae C36:2, there were seven and five
significantly correlated diacyl-phosphatidylcholines, respectively.
For five metabolites, PC aa C32:1, PC aa (OH,COOH) C30:3,
PC aa C34:1, PC aa C34:0 and PC aa C36:1, the ratios with the
three acyl-alkyl-phosphatidylcholines were all significantly corre-
lated with the nicotine consumption. These results further suggest
that smokers have higher concentrations of diacyl-phospholipids
and lower concentrations of the plasmalogens, whereas the
opposite is seen in former and non-smokers. Notably, these five
diacyl-phospholipids were found to have the most significant p-
value of ANOVA and Wilcoxon tests based on the single
metabolite study (Table 1). For the most statistically significant
five metabolites, the results based on single metabolites and ratios
of metabolites pairs agree with each other.
Discussion
Our data provide clear evidence that metabolic profiling reflects
human metabolism. We calculated correlation of all metabolite
concentration pairs. Clustering results revealed that metabolites in
related functional contexts are highly correlated. This is also
consistent with similar conclusions of a mouse study based on 67
studied metabolites [26]. This demonstrates that metabolic profiles
are biologically and statistically meaningful.
We applied our metabolic profiling to investigate the impact of
cigarette smoking. Significant changes were observed mainly for
clusters of lipid metabolites. Moreover, the 23 biomarkers that we
could identify are all lipids, consistent with the observation that cell
membranes are affected or damaged due to the influence of
tobacco smoking [27]. The physiological importance of lipids is
illustrated by the numerous diseases to which lipid abnormalities
contribute, including atherosclerosis, diabetes, obesity, and
Alzheimer’s disease [28]. Lipids are major components of
biological membranes, which maintain the integrity of cells and
allow the compartmentalization of the cytoplasm into specific
organelles. Cigarette smoke, then, might affect or even damage
cell membranes, thus influencing the concentrations of related
metabolites, namely the biomarkers discovered in this study.
Glycerophospholipid metabolism and ether lipid metabolism
share one small molecule, 1-acyl-glycerone 3-phosphate
[29,30,31]. In the ether lipid metabolism pathway, a unique
Table 2. Significantly correlated ratios of metabolite concentration with smoker phenotype
Metabolite M1 Metabolite M2 n-cases Ratio (M1/M2) Ratio (M2/M1)
rp -value rp -value
PC ae C40:6 PC aa C32:1 283 0.333 9.5E-09 20.378 5.0E-11
PC ae C40:6 PC aa (OH, COOH) C30:3 283 0.317 4.8E-08 20.398 3.7E-12
PC ae C40:6 PC aa C34:1 283 0.320 3.7E-08 20.393 6.6E-12
PC ae C40:6 PC aa C34:0 283 0.339 4.8E-09 20.393 7.1E-12
PC ae C40:6 PC aa C36:0 283 0.317 4.8E-08 20.360 4.4E-10
PC ae C40:6 PC aa C38:5 283 0.317 5.3E-08 20.346 2.3E-09
PC ae C40:6 PC aa C40:6 283 0.314 7.0E-08 20.396 4.6E-12
PC ae C40:6 PC aa C38:3 283 0.317 5.1E-08 20.395 5.6E-12
PC ae C40:6 PC aa C40:4 283 0.313 7.3E-08 20.352 1.1E-09
PC ae C40:6 PC aa C40:5 283 0.356 7.0E-10 20.403 1.9E-12
PC ae C40:6 PC aa C38:2 283 0.302 2.2E-07 20.385 1.9E-11
PC ae C40:6 PC aa C36:1 283 0.305 1.6E-07 20.387 1.5E-11
PC ae C40:6 SM (OH, COOH) C16:1 283 0.329 1.4E-08 20.377 5.4E-11
PC ae C40:6 SM OH C20:3 283 0.315 6.5E-08 20.345 2.4E-09
PC ae C38:2 PC aa C32:1 283 0.326 1.9E-08 20.364 2.8E-10
PC ae C38:2 PC aa C38:3 283 0.313 7.9E-08 20.346 2.2E-09
PC ae C38:2 PC aa C34:0 283 0.317 5.0E-08 20.377 5.2E-11
PC ae C38:2 PC aa C36:1 283 0.316 5.5E-08 20.358 5.7E-10
PC ae C38:2 PC aa C34:1 283 0.305 1.6E-07 20.363 3.2E-10
PC ae C38:2 PC aa C38:2 283 0.300 2.8E-07 20.342 3.6E-09
PC ae C38:2 PC aa (OH, COOH) C30:3 283 0.309 1.1E-07 20.352 1.1E-09
PC ae C36:2 PC aa C36:1 283 0.320 3.7E-08 20.335 7.3E-09
PC ae C36:2 PC aa (OH, COOH) C30:3 283 0.309 1.2E-07 20.344 2.8E-09
PC ae C36:2 PC aa C34:0 283 0.304 1.8E-07 20.342 3.7E-09
PC ae C36:2 PC aa C34:1 283 0.303 2.0E-07 20.341 4.0E-09
PC ae C36:2 PC aa C32:1 283 0.301 2.5E-07 20.327 1.7E-08
Two metabolites M1 and M2 are listed in the first two columns. Pearson’s correlation coefficient r of metabolite ratios of M1/M2 and M2/M1 positively and negatively
correlated with smoker phenotype are shown in columns 4 and 6, respectively. The corresponding p-values of n-cases of t-tests are indicated in columns 5 and 7,
respectively.
doi:10.1371/journal.pone.0003863.t002
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phosphate synthase (alkyl-DHAP, EC 2.5.1.26) resulting in the
formation of the ether bond by replacement of the sn-1 fatty acid
with a long chain fatty alcohol (Figure 5). The following
biosynthesis steps in both ether lipid and diacyl-phospholipids
converge in a reaction catalyzed by acylglycerone phosphate
reductase (EC 1.1.1.101), which is utilized in the synthesis of both
ether lipids and diacylated phopholipids [32]. Following similar
synthesis steps in the ether lipid and glycerophospholipid
pathways, acyl-alkyl-phosphatidylcholines and diacyl- phosphati-
dylcholines will be either intermediate or end products of the two
pathways. Alkylglycerone phosphate synthase is encoded by AGPS,
the gene in Homo sapiens. Interestingly, in a human lung project
[33], it was found that the AGPS gene expression is highly
Figure 4. Significantly corrected pairs of metabolites with smoking phenotype. Significantly correlated pairs of metabolites are
demonstrated by dashed lines. For more details, see Table 2. Similar classes of metabolites are shown with the same color.
doi:10.1371/journal.pone.0003863.g004
Figure 5. In smokers, reduced or lack of activity of the enzyme alkyl-DHAP may further regulate the ratio of acyl-alkyl- to diacyl-
phosphatidylcholines in the ether lipid- and glycerophospholipid pathways. Part of the pathways of the glycerophospholipid- and ether
lipid metabolism are shown. The names of the small molecular are indicated. Enzymes alkylglycerone phosphate synthase (alkyl-DHAP, EC 2.5.1.26)
and acylglycerone phosphate reductase (EC 1.1.1.101) are shown in red and blue.
doi:10.1371/journal.pone.0003863.g005
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(Figure S6). The upregulation of alkyl-DHAP seen in our
metabolite profiles and independent in a gene expression study
further corroborates its role in defects linked to smoking.
Human newborns of nicotine-exposed pregnancies reveal
growth retardation due to impairment of uteroplacental circula-
tion as a result of the vasoconstricting effect of nicotine [34].
Studies in the rat showed that mechanisms involving deterioration
development of fetal alveolae and up regulation of lipid
peroxidation by P450 enzymes [35,36]. In this respect, our study
provides a novel insight in that nicotine affects plasmalogen levels.
Plasmalogen comprise a major portion of the phospholipids in the
adult human central nervous system. Overall, it was shown that
newborn plasmalogen levels are relatively low (7% of total
phospholipid mass) [32]. As the plasmalogens may influence the
surface tension in alveolar surfactants [37], we hypothesize that
this would be triggered as well by nicotine. Isolated (single gene
defect) deficiency in human AGPS gene function further indicate
that this gene is embryonic essential and its inactivation leads to a
lethal phenotype [38,39]. This gene is also affected in other
disorders of biogenesis, such as Zellweger Syndrome or Rhizo-
melic chodrodisplasia punctata type 3 [40]. Therefore, all factors
that influence ether lipid balance, including nicotine as shown
here, are of potential risk to human health.
Our metabolic profiling provides a snapshot of the complex
human metabolome. More detailed profiles in combination with
kinetic experiments for blood sample collection are necessary to
draw a comprehensive map and will reflect physiological processes
as responses to developmental, genetic or environmental factors
[16,17,41,42].
The 198 detected metabolites are a large dataset in human
blood samples, though much smaller in comparison to the human
metabolomics database, which currently has a collection of about
2,500 metabolites [43]. Previously identified biomarkers of ND
metabolites [9,44], such as nicotine, cotinine and carbon
monoxide, are not in our dataset. In addition to further technical
improvements in metabolite detection sensitivity, samples from
urine and other tissues are needed to enlarge our dataset.
Our study represents the first large screen of metabolites to
study the influence of cigarette smoking on human blood serum.
Albeit we are aware that the sample size of current smokers in this
pilot study is small, our results are encouraging and we could show
that the smokers are distinctly separated from former and non-
smokers. In general, similar observations were obtained at an
individual level, though with large variance. An interesting
observation is that former smokers were found to be separated
from non-smokers, suggesting that the influence of cigarette smoke
in human blood remains for years. We note, however, that the
group of former smokers is not well-defined in this study because
the time when these individuals quit smoking is not documented.
Damage to the cell membrane from smoking may be reversed
over time due to the repair mechanisms in the human body
[45,46].
The independent but consistent observation from our metabolic
profile analysis and AGPS gene expression data may indicate that
smoking affects the enzymatic activity of alkyl-DHAP and thus
change the ratios of two types of metabolites. However, the overall
fat metabolism is likely not be affected, as the BMI does not vary
significantly between the groups of current, former and non-
smokers (data not shown).
Our analyses suggest that small molecules that activate the
enzyme alkyl-DHAP could be developed to treat plasmalogens
deficiency disorders that are caused by nicotine consumption in
smokers.
Materials and Methods
Sample Source
KORA (Cooperative Health Research in the Region of
Augsburg) is a population-based research platform with subse-
quent follow-up studies in the fields of epidemiology, health
economics and health care research [5,6,7]. It is based on
interviews in combination with medical and laboratory examina-
tions, as well as the collection of biological samples. Answers from
the participants were found to be reliable [47]. Details about the
questionnaire forms and variables can be found at KORA-gen [5]:
http://epi.gsf.de/kora-gen/. Four surveys were conducted with
18,079 participants. KORA-S3 consists of representative samples
from 4,856 individuals. The dataset comprises individuals aged
25–74 years resident in the region of Augsburg, Southern
Germany, examined in 1994–1995. During the years 2004–
2005, 2,974 participants participated in a follow-up (KORA-F3)
survey of the one conducted 10 years ago. For all studies, we
obtained written consent from participants and approval from the
local ethical committees.
Sampling
Randomly selected population-based 283 male participants
(aged 55–79 years) of KORA-F3 were used in the current study.
Of the 283 individuals, 28 were current smokers (S), who smoked
one to 50 (mean 17) cigarettes per day. Out of the 28 smokers,
only nine completed the Fagersto ¨m test of ND form (FTND), the
score of which reflects the addiction level of dependence on
nicotine, and these data were not used in this study. Those who
ceased smoking but smoked at least one cigarette daily were
classified as former smokers. Non smokers had never smoked at
the time when the study was conducted while 154 and 101 were
former smokers (fS) and non-smokers (nS), respectively.
In KORA study, to characterize the nicotine consumption, the
current smoker is defined as 1; sometimes smoker is defined as 2;
former and non-smoker are quantified as 3 and 4, respectively.
Blood samples were collected in 2006. The standardized
biological sample collections applied have been described in detail
previously [5,6,7,48]. Blood was drawn in the morning between 8
and 10 am and was immediately horizontal shaken for 10 minutes,
followed by 40 minutes resting at 4uC to obtain complete
coagulation, and finally centrifugation of blood was performed
at 2000g, 4uC for 10 minutes for serum collection. Serum was
aliquoted and kept for 2–4 hours at 4uC, after which it was frozen
at 280uC until metabolic analyses.
Metabolite measurements
Targeted metabolite profiling by electrospray ionization (ESI)
tandem mass spectrometry (MS/MS) was performed on a fee-for-
service basis on a quantitative metabolomics platform at Biocrates
Life Sciences AG, Austria. The company had no access to phenotype
information that would have permitted any data prefiltering other
than objective quality control for measurement errors based on
internal controls and duplicates. All metabolomics data was used
as received from Biocrates. We did not apply any data correction,
nor were any data points removed. The experimental metabo-
lomics measurement technique is described in detail by patent US
2007/0004044 (accessible online at http://www.freepatentsonline.
com/20070004044.html). A summary of the method can be found
in [28,49,50]. Briefly, a targeted profiling scheme is used to
quantitatively screen for known small molecule metabolites using
multiple reaction monitoring, neutral loss and precursor ion scans.
Quantification of the metabolites of the biological sample is
achieved by reference to appropriate internal standards. The
Metabolic Profiling Analysis
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of Federal Regulations) Part 11, which implies proof of
reproducibility within a given error range. It has been applied in
different academic and industrial applications [51,52]. Concen-
trations of all analyzed metabolites are reported in mM.
Analyses of Metabolites
A total of 363 metabolites were targeted. Due to variability in
experimental values some were excluded to ensure robustness of
dataset. In the current study, 198 metabolites were used for
subsequent analyses with an above 95 percent detection rate for
each metabolite. Missing values were replaced with population
mean for multivariate analysis.
The metabolomics dataset (for abbreviation and biochemical
name see Table S1) contains 18 amino acids, eight sugars, six
biogenic amines, four prostaglandins, 29 acylcarnitines, 44
sphingolipids and 89 glycerophospholipids with different head
groups and are further differentiated with respect to the presence
of ester (a) and ether (e) bonds in the glycerol moiety, where two
letters (aa=diacyl, ae=acyl-alkyl, ee=dialkyl) denote that two
glycerol positions are bound to a fatty acid residue, while a single
letter (a=acyl or e=alkyl) indicates the presence of a single fatty
acid residue. Lipid side chain composition is abbreviated as Cx:y,
where x denotes the number of carbons in the side chain and y the
number of double bonds. The precise position of the double bonds
and the distribution of the carbon atoms in different fatty acid side
chains cannot be determined with this technology. In the current
study, we used only the most likely metabolites, whereas possible
alternative assignments were not indicated for cases where
mapping of metabolite names to individual masses was ambigu-
ous.
Statistical Analysis
Pearson’s correlation coefficient, hierarchical clustering meth-
ods and Euler’s distance were employed and calculation was done
in R platform (http://www.r-project.org/). Results of pair-wise
correlations of the metabolites and clustering were illustrated by
heat maps [53].
Three multivariate statistical methods, partial least squares
discriminant analysis (PLS-DA), principal component analysis
(PCA) and correspondence analysis (CA), were used
[14,19,20,21,22]. PLS-DA used partial least squares regression
models for classification and it bears some relation to PCA; Instead
of finding the hyper planes of maximum variance, it finds a linear
model describing some predicted variables (e.g. the behavior of
smokers) in terms of observable variables (e.g. detected metabolites
concentrations). PLS-DA and PCA normalizes the populations to
have a mean of zero and a standard deviation of one for every
metabolite; In CA normalization, however, the whole matrix is
defined to be one and each element is a portion of one. CA has the
advantage that the sample size needs not to be bigger than the size
of variables. All the calculations were done in R platform (http://
www.r-project.org/). Besides the basic packages in R, we use CA
and PLS, as well as the required packages by them. PCA is using
‘‘stats’’ the function: princomp. All these packages can be
downloaded at http://www.r-project.org.
Differences among two or more independent groups were
tested by one-way ANOVA and two-tailed test [23].
Furthermore, a non-parametric Wilcoxon test was performed
[24,25] to determine whether the concentration of each small
molecule was significantly different in the two groups
compared.
Supporting Information
Table S1 The abbreviation, class and biochemical name of each
metabolite. For each metabolite, the abbreviation, class and
biochemical name is listed in the first to third columns, respectively.
Found at: doi:10.1371/journal.pone.0003863.s001 (0.05 MB
XLS)
Figure S1 Classification of the 198 metabolites based on
population-based KORA samples (n=283): part 1. Each square
represents the Pearson’s correlation coefficient between the
metabolite of the column with that of the row. Metabolite order
is determined as in hierarchical clustering and the corresponding
name of metabolite is shown in Figure S2, due to space limitation.
Found at: doi:10.1371/journal.pone.0003863.s002 (3.42 MB TIF)
Figure S2 Classification of the 198 metabolites based on
population-based KORA samples (n=283): part 2. The corre-
sponding name of each metabolite is shown.
Found at: doi:10.1371/journal.pone.0003863.s003 (1.76 MB TIF)
Figure S3 Classification of the 198 metabolites by removing the
28 current smokers from the date set (n=255): part 1. Each square
represents the Pearson’s correlation coefficient between the
metabolite of the column with that of the row. Metabolite order
is determined as in hierarchical clustering and the corresponding
name of metabolite is shown in Figure S4, due to space limitation.
Found at: doi:10.1371/journal.pone.0003863.s004 (3.47 MB TIF)
Figure S4 Classification of the 198 metabolites by removing the
28 current smokers from the date set (n=255): part 2. The
corresponding name of metabolite is shown.
Found at: doi:10.1371/journal.pone.0003863.s005 (1.69 MB TIF)
Figure S5 Multivariate analysis results of 198 metabolites in 283
serum human samples. (A) Three dimensional PLS-DA results of
283 individuals. The 28 current smokers are displayed in red,
while 154 former smokers and 101 non-smokers are indicated in
blue and green, respectively. (B) Three dimensional PCA results.
(C) Three dimensional CA results.
Found at: doi:10.1371/journal.pone.0003863.s006 (1.48 MB TIF)
Figure S6 Gene expression results of AGPS (Gruber et al., 2006).
Source can be found: http://www.ncbi.nlm.nih.gov/geo/gds/
profileGraph.cgi?&dataset=aXH3AG-CCJRMHhztsoqdPGHQLF-
PQLCCGG69sriID&dataset=kkflcfmdegihflmmmmmlhffihfhigeeff-
klmmlfe$&gmin=35.410000&gmax=292.510000&absc=&gds=
1673&idref=205401_at&annot=AGPS. With kind permission of
Dr. Mark Geraci.
Found at: doi:10.1371/journal.pone.0003863.s007 (1.83 MB TIF)
Acknowledgments
We thank C. Schultz, Y. Ning, G. Ding, W. Sauter, P. Ro ¨ßler, N. Klopp,
H. Grallert, H. Gohlke, B. Kranz, A. Do ¨ring, A. Peters, H.W. Mewes and
M. Sattler for comments, discussions and suggestions. We express our
appreciation to all KORA study participants for donating their blood and
time. The KORA group consists of H.E. Wichmann (speaker), A. Peters,
C. Meisinger, T. Illig, R. Holle, and J. John and their co-workers, who are
responsible for the design and conduct of the KORA studies.
Author Contributions
Conceived and designed the experiments: CG HEW JA KS TI. Performed
the experiments: KMW. Analyzed the data: RWS YY KM EL EA CG
KHL ND PH LL YL HEW JA KS TI. Contributed reagents/materials/
analysis tools: RWS YY JA KS TI. Wrote the paper: RWS YY KM CG
JA.
Metabolic Profiling Analysis
PLoS ONE | www.plosone.org 9 December 2008 | Volume 3 | Issue 12 | e3863References
1. Mackay J, Eriksen M, Shafey O (2006) The Tobacco Atlas, 2nd edition. The
American Cancer Society.
2. Li MD (2006) The genetics of nicotine dependence. Curr Psychiatry Rep 8:
158–164.
3. Xavier F, Henn Lde A, Oliveira M, Orlandine L (1996) Smoking and its relation
to the histological type, survival, and prognosis among patients with primary
lung cancer. Sao Paulo Med J 114: 1298–1302.
4. Sauter W, Rosenberger A, Beckmann L, Kropp S, Mittelstrass K, et al. (2008)
Matrix metalloproteinase 1 (MMP1) is associated with early-onset lung cancer.
Cancer Epidemiol Biomarkers Prev 17: 1127–1135.
5. Wichmann HE, Gieger C, Illig T (2005) KORA-gen–resource for population
genetics, controls and a broad spectrum of disease phenotypes. Gesundheitswe-
sen 67 Suppl 1: S26–30.
6. Loewel H, Doering A, Schneider A, Heier M, Thorand B, et al. (2005) The
MONICA Augsburg surveys–basis for prospective cohort studies. Gesundheits-
wesen 67 Suppl 1: S13–18.
7. Holle R, Happich M, Lowel H, Wichmann HE (2005) KORA–a research
platform for population based health research. Gesundheitswesen 67 Suppl 1:
S19–25.
8. Jaleel A, Jaleel F, Majeed R, Alam E (2007) Leptin and Blood Lipid Levels in
Smokers and ex Smokers. World Applied Sciences Journal 2: 348–352.
9. Leone A (2005) Biochemical markers of cardiovascular damage from tobacco
smoke. Curr Pharm Des 11: 2199–2208.
10. Hecht SS, Murphy SE, Carmella SG, Zimmerman CL, Losey L, et al. (2004)
Effects of reduced cigarette smoking on the uptake of a tobacco-specific lung
carcinogen. J Natl Cancer Inst 96: 107–115.
11. Joseph AM, Hecht SS, Murphy SE, Carmella SG, Le CT, et al. (2005)
Relationships between cigarette consumption and biomarkers of tobacco toxin
exposure. Cancer Epidemiol Biomarkers Prev 14: 2963–2968.
12. Nicholson JK, Wilson ID (2003) Opinion: understanding ‘global’ systems
biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov
2: 668–676.
13. Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, et al. (2007) Metabolic
profiling, metabolomic and metabonomic procedures for NMR spectroscopy of
urine, plasma, serum and tissue extracts. Nat Protoc 2: 2692–2703.
14. Ala-Korpela M (2007) Potential role of body fluid 1H NMR metabonomics as a
prognostic and diagnostic tool. Expert Rev Mol Diagn 7: 761–773.
15. Holmes E, Loo RL, Stamler J, Bictash M, Yap IK, et al. (2008) Human
metabolic phenotype diversity and its association with diet and blood pressure.
Nature 453: 396–400.
16. Assfalg M, Bertini I, Colangiuli D, Luchinat C, Schafer H, et al. (2008) Evidence
of different metabolic phenotypes in humans. Proc Natl Acad Sci U S A 105:
1420–1424.
17. Shaham O, Wei R, Wang TJ, Ricciardi C, Lewis GD, et al. (2008) Metabolic
profiling of the human response to a glucose challenge reveals distinct axes of
insulin sensitivity. Mol Syst Biol 4: 214.
18. Makinen VP, Soininen P, Forsblom C, Parkkonen M, Ingman P, et al. (2008) 1H
NMR metabonomics approach to the disease continuum of diabetic complica-
tions and premature death. Mol Syst Biol 4: 167.
19. Gavaghan CL, Wilson ID, Nicholson JK (2002) Physiological variation in
metabolic phenotyping and functional genomic studies: use of orthogonal signal
correction and PLS-DA. FEBS Lett 530: 191–196.
20. Reich D, Price AL, Patterson N (2008) Principal component analysis of genetic
data. Nat Genet 40: 491–492.
21. Robertson DG, Reily MD, Baker JD (2007) Metabonomics in pharmaceutical
discovery and development. J Proteome Res 6: 526–539.
22. Wang-Sattler R, Blandin S, Ning Y, Blass C, Dolo G, et al. (2007) Mosaic
Genome Architecture of the Anopheles gambiae Species Complex. PLoS ONE
2: e1249.
23. Chambers JM, Hastie TJ (1992) Statistical Models in S: Wadsworth & Brooks/
Cole.
24. Bauer DF (1972) Constructing Confidence Sets Using Rank Statistics. Journal of
the American Statistical Association 67: 687–690.
25. Hollander M, Wolfe DA (1973) Nonparametric statistical inference: New York:
John Wiley & Sons.
26. Ferrara CT, Wang P, Neto EC, Stevens RD, Bain JR, et al. (2008) Genetic
networks of liver metabolism revealed by integration of metabolic and
transcriptional profiling. PLoS Genet 4: e1000034.
27. Yildiz D, Ercal N, Armstrong DW (1998) Nicotine enantiomers and oxidative
stress. Toxicology 130: 155–165.
28. Watson AD (2006) Thematic review series: systems biology approaches to
metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid
analysis in biological systems. J Lipid Res 47: 2101–2111.
29. Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes.
Nucleic Acids Res 28: 27–30.
30. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, et al. (2006) From
genomics to chemical genomics: new developments in KEGG. Nucleic Acids
Res 34: D354–357.
31. Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, et al. (2008) KEGG for
linking genomes to life and the environment. Nucleic Acids Res 36: D480–484.
32. Nagan N, Zoeller RA (2001) Plasmalogens: biosynthesis and functions. Prog
Lipid Res 40: 199–229.
33. Gruber MP, Coldren CD, Woolum MD, Cosgrove GP, Zeng C, et al. (2006)
Human lung project: evaluating variance of gene expression in the human lung.
Am J Respir Cell Mol Biol 35: 65–71.
34. Mochizuki M, Maruo T, Masuko K, Ohtsu T (1984) Effects of smoking on
fetoplacental-maternal system during pregnancy. Am J Obstet Gynecol 149:
413–420.
35. Rehan VK, Wang Y, Sugano S, Santos J, Patel S, et al. (2007) In utero nicotine
exposure alters fetal rat lung alveolar type II cell proliferation, differentiation,
and metabolism. Am J Physiol Lung Cell Mol Physiol 292: L323–333.
36. Wang T, Chen M, Yan YE, Xiao FQ, Pan XL, et al. (2008) Growth retardation
of fetal rats exposed to nicotine in utero: Possible involvement of CYP1A1,
CYP2E1, and P-glycoprotein. Environ Toxicol.
37. Rudiger M, Kolleck I, Putz G, Wauer RR, Stevens P, et al. (1998) Plasmalogens
effectively reduce the surface tension of surfactant-like phospholipid mixtures.
Am J Physiol 274: L143–148.
38. Ofman R, Lajmir S, Wanders RJ (2001) Etherphospholipid biosynthesis and
dihydroxyactetone-phosphate acyltransferase: resolution of the genomic organi-
zation of the human gnpat gene and its use in the identification of novel
mutations. Biochem Biophys Res Commun 281: 754–760.
39. Wanders RJ, Schutgens RB, Schrakamp G, van den Bosch H, Tager JM, et al.
(1986) Infantile Refsum disease: deficiency of catalase-containing particles
(peroxisomes), alkyldihydroxyacetone phosphate synthase and peroxisomal beta-
oxidation enzyme proteins. Eur J Pediatr 145: 172–175.
40. Wanders RJ, Dekker C, Hovarth VA, Schutgens RB, Tager JM, et al. (1994)
Human alkyldihydroxyacetonephosphate synthase deficiency: a new peroxisom-
al disorder. J Inherit Metab Dis 17: 315–318.
41. Weckwerth W, Fiehn O (2002) Can we discover novel pathways using
metabolomic analysis? Curr Opin Biotechnol 13: 156–160.
42. Weckwerth W (2003) Metabolomics in systems biology. Annu Rev Plant Biol 54:
669–689.
43. Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, et al. (2007) HMDB: the
Human Metabolome Database. Nucleic Acids Res 35: D521–526.
44. Gochman E, Reznick AZ, Avizohar O, Ben-Amotz A, Levy Y (2007) Exhaustive
exercise modifies oxidative stress in smoking subjects. Am J Med Sci 333:
346–353.
45. Reddy A, Caler EV, Andrews NW (2001) Plasma membrane repair is mediated
by Ca(2+)-regulated exocytosis of lysosomes. Cell 106: 157–169.
46. Bansal D, Miyake K, Vogel SS, Groh S, Chen CC, et al. (2003) Defective
membrane repair in dysferlin-deficient muscular dystrophy. Nature 423:
168–172.
47. Huth C, Siegert N, Meisinger C, Konig J, Kaab S, et al. (2007) Individuals with
very low alcohol consumption: a heterogeneous group. J Stud Alcohol Drugs 68:
6–10.
48. Doering A, Gieger C, Mehta D, Gohlke H, Prokisch H, et al. (2008) SLC2A9
influences uric acid concentrations with pronounced sex-specific effects. Nat
Genet 40: 430–436.
49. Weinberger KM (2008) [Metabolomics in diagnosing metabolic diseases]. Ther
Umsch 65: 487–491.
50. Unterwurzacher I, Koal T, Bonn GK, Weinberger KM, Ramsay SL (2008)
Rapid sample preparation and simultaneous quantitation of prostaglandins and
lipoxygenase derived fatty acid metabolites by liquid chromatography-mass
spectrometry from small sample volumes. Clin Chem Lab Med.
51. Altmaier E, Ramsay SL, Graber A, Mewes HW, Weinberger KM, et al. (2008)
Bioinformatics analysis of targeted metabolomics-uncovering old and new tales
of diabetic mice under medication. Endocrinology.
52. Gieger C, Geistlinger L, Altmaier E, de Angelis MH, Kronenberg F, et al. (2008)
Genetics meets metabolomics: a genome-wide association study of metabolite
profiles in human serum. PLoS Genet in presse.
53. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and
display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95:
14863–14868.
Metabolic Profiling Analysis
PLoS ONE | www.plosone.org 10 December 2008 | Volume 3 | Issue 12 | e3863